Literature DB >> 16464965

Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation.

Margaret M Doherty1, Karen Poon, Carol Tsang, K Sandy Pang.   

Abstract

Binding, transport, and metabolism are factors that influence morphine (M) removal in the rat liver. For M and the morphine 3beta-glucuronide metabolite (M3G), modest binding existed with 4% bovine serum albumin (unbound fractions of 0.89 +/- 0.07 and 0.98 +/- 0.09, respectively), and there was partitioning of M into red blood cells. Transport studies of M (<750 microM) showed similar, concentration-independent uptake clearances (CLs) of 1.5 ml min(-1) g(-1) among zonal and homogeneous, isolated rat hepatocytes. Transport of M3G, ascertained in multiple indicator dilution studies at various steady-state M3G concentrations (10-262 microM), uncovered a low and concentration-independent influx clearance (<10% of flow rate). The outflow dilution curve of [(3)H]M3G was superimposable onto that of [(14)C]sucrose, the extracellular reference, displaying similarity in transit times (23.5 and 22.2 s), negligible biliary excretion, and almost complete dose recovery from perfusate. In contrast, M3G occurred abundantly in both perfusate and bile in single-pass perfusion studies of the precursor, M, and revealed a biliary clearance of formed M3G that was 12.3-fold that of preformed M3G, suggesting a sinusoidal, diffusional barrier for M3G. With increasing concentrations of M (9-474 microM), clearance decreased, and metabolism and biliary excretion displayed concentration-dependent kinetics. Fitting of the data to a physiologically based liver model revealed that M removal mechanisms were saturable, with a K(m,met) of 52.2 microM and V(max,met) of 58.8 nmol min(-1) g(-1) for metabolism, and a K(m,ex) of 41.2 microM and V(max,ex) of 8.1 nmol min(-1) g(-1) for excretion. Sinusoidal transport was not rate-limiting for M removal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464965     DOI: 10.1124/jpet.105.100446

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

4.  Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.

Authors:  Cen Guo; Kyunghee Yang; Kenneth R Brouwer; Robert L St Claire; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2016-05-27       Impact factor: 4.030

5.  A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism.

Authors:  Pavel Gris; Josee Gauthier; Philip Cheng; Dustin G Gibson; Denis Gris; Oskar Laur; John Pierson; Sean Wentworth; Andrea G Nackley; William Maixner; Luda Diatchenko
Journal:  Mol Pain       Date:  2010-06-02       Impact factor: 3.395

6.  From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties.

Authors:  E H J Krekels; T N Johnson; S M den Hoedt; A Rostami-Hodjegan; M Danhof; D Tibboel; C A J Knibbe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-10-10

7.  Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.

Authors:  Folabomi A Oladosu; Matthew S Conrad; Sandra C O'Buckley; Naim U Rashid; Gary D Slade; Andrea G Nackley
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.